Literature DB >> 13082420

Phenylbutazone: an evaluation of its use.

W G SNOW.   

Abstract

Phenylbutazone (Butazolidin(R)), one of the newer antirheumatic drugs, while providing varying degrees of symptomatic relief in various types of rheumatism, may also cause serious toxic side effects. It is most effective in acute gout, and slightly less so in rheumatoid arthritis, of both the spondylitic and peripheral types. Its use in degenerative arthritis is not indicated. Its toxic side effects include gastrointestinal upsets, edema, rash, stomatitis, purpura, hematuria, agranulocytosis and reactivation of peptic ulcer. Several fatalities have been reported. It is, however, a valuable drug if used properly. Extreme caution should be exercised in selection of patients, in administration of the drug and in continuous observation of patients receiving it.

Entities:  

Keywords:  ANALGESICS/therapeutic use; RHEUMATISM/therapy

Mesh:

Substances:

Year:  1953        PMID: 13082420      PMCID: PMC1521846     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  11 in total

1.  Agranulocytosis following phenylbutazone therapy.

Authors:  S C WERBLOW; J NEBER
Journal:  J Am Med Assoc       Date:  1953-04-11

2.  Current principles of management in gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1952-12       Impact factor: 4.965

3.  Clinical evaluation of phenylbutazone.

Authors:  R M PATTERSON; J F BENSON; P L SCHOENBERG
Journal:  U S Armed Forces Med J       Date:  1953-01

4.  Butazolidin in rheumatoid disorders; a preliminary report.

Authors:  C H SMITH; H G KUNZ
Journal:  J Med Soc N J       Date:  1952-07

5.  Phenylbutazone (butazolidin) in rheumatoid arthritis and gout.

Authors:  W C KUZELL; R W SCHAFFARZICK; B BROWN; E A MANKLE
Journal:  J Am Med Assoc       Date:  1952-06-21

6.  Unusual reaction following use of phenylbutazone (butazolidin).

Authors:  R CHARET; I SIEGEL
Journal:  J Am Med Assoc       Date:  1953-02-14

7.  The effect of butazolidin (phenylbutazone) on water and electrolyte excretion.

Authors:  E L WILKINSON; H BROWN
Journal:  Am J Med Sci       Date:  1953-02       Impact factor: 2.378

8.  Agranulocytosis following use of phenylbutazone (butazolidin).

Authors:  E BERSHOF; A C OXMAN
Journal:  J Am Med Assoc       Date:  1953-02-14

9.  Phenylbutazone (butazolidin) and butapyrin; a study of clinical effects in arthritis and gout.

Authors:  W C KUZELL; R W SCHAFFARZICK
Journal:  Calif Med       Date:  1952-11

10.  Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis.

Authors:  C A L STEPHENS; E E YEOMAN; W P HOLBROOK; D F HILL; W L GOODIN
Journal:  J Am Med Assoc       Date:  1952-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.